Contact us and reporting concerns

 

If you have any supply problems, please contact us. Contacting UCBCares® is simple. Anything you share will be treated confidentially.

Office

 

Come say hello at our office HQ.

 

UCB Pharma S.A.
Alée de la Recherche 60
1070 Bruxelles - Belgique

Phone

 

Mon-Fri from 8am to 5pm.

 

Charged Call
+32 2 559 92 00

 

Freephone
From Belgium: 0800 38008

 

Email

 

Our friendly team is here to help.

 

UCBCares@ucb.com

UCBCares-page-employee

UCBCares®

 

UCBCares® is a helpline offered by UCB to people living with chronic diseases on a UCB medication, and their healthcare professionals. Our team on the phone is here to support you. 

 

From the moment you contact UCBCares®, a member of our dedicated team will help you with the following:

 

  • Share guidance which can help you to better understand and manage your treatment
  • Answer your questions about UCB medicines 
  • Listen to and record any side effects or complaints you may have with your UCB medicine

Visit UCBCares®

Report adverse events

 

If you wish to report an adverse event related to one of our products, please follow the current regulatory procedure in force in your country or click on the following link to access the contact page of the UCB corporate website where you can report adverse events to UCB local affiliate contacts or UCB Cares®.

 

If you are a user from United Kingdom or Ireland, reporting forms and information can be found at Yellow Card Reporting Site for the UK and Report an issue for Ireland. Adverse events should also be reported to UCB.

 

Report an adverse event
Image

Got a question?

Feel free to request time with an UCB representative so they can discus your question in more detail with you.

This form is not reporting an adverse event or a product complaint. If you wish to do so, please follow the current regulatory procedure in force in your country or contact us using the webform available here.

How relevant is this content to you?
Not relevant
Highly relevant
Help us deliver more relevant content to you

EU-DA-2300301

Date of preparation: November 2023